

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4441289

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RINAT NEUROSCIENCE CORP.	12/20/2012
RECEIVING PARTY DATA	
Name:	LABRYS BIOLOGICS, INC.
Street Address:	1700 OWENS STREET
Internal Address:	#595
City:	SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94158
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15588432
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 368-2162
Email:	apsi@fr.com
Correspondent Name:	ELIZABETH KARNAS
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	43612-0002013
NAME OF SUBMITTER:	RITA M. LISTON
SIGNATURE:	/Rita M. Liston/
DATE SIGNED:	06/02/2017
Total Attachments: 3	
source=43612_0002013_Rinat_Labrys#page1.tif	
source=43612_0002013_Rinat_Labrys#page2.tif	
source=43612_0002013_Rinat_Labrys#page3.tif	

CORPORATE TO CORPORATE ASSIGNMENT	Docket Number 43189-701
<p>WHEREAS, <u>Rinat Neuroscience Corp.</u>, a Delaware Corporation, (hereinafter "Assignor"), owns the entire right, title and interest in and to the patents and patent applications listed in the attached Exhibit A (hereinafter "Assigned Patents"), and in and to all inventions disclosed in said Assigned Patents (collectively "Inventions"). The term "Assigned Patents" also includes any renewal, divisional, continuation, continuation-in-part, or request for continued examination of any of such patents, certificates of invention and patent applications, and any and all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, certificates of correction, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing, including any and all applications procedurally related to such patents legally filed after October 10, 2012.</p> <p>WHEREAS, <u>Labrys Biologics, Inc.</u>, a corporation of the State of <u>Delaware</u>, having a place of business at <u>1700 Owens Street #595, San Francisco, California 94158</u>, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Assigned Patents and Inventions.</p> <p>NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:</p> <ol style="list-style-type: none"> 1. Said Assignor hereby sells, assigns, transfers and conveys unto said Assignee its entire right, title and interest (a) in and to said Inventions and said Assigned Patents, including the right to claim priority to said Inventions and said Assigned Patents; and (b) in and to all claims for past, present, and future infringement of the Assigned Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patent(s). 2. To the extent that Assignee prepares, files, prosecutes, or maintains, or causes others to prepare, file, prosecute, or maintain, patents or patent applications (either provisional or non-provisional) included in the Assigned Patents or Inventions, Assignor, its employees, attorneys, or other representatives shall reasonably cooperate in the preparation, filing, prosecution, and maintenance thereof. Assignor agrees that its employees, attorneys, or other representatives will timely execute, whenever requested by Assignee, all applications, assignments, lawful oaths, and any other papers prepared by Assignee or its patent agents which Assignee may deem necessary or desirable for securing to Assignee or for maintaining for Assignee any of the rights being assigned by Assignor to Assignee in any of the Assigned Patents and Inventions. 3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives. 4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith. 5. Said Assignor hereby request that any patents issuing from the Assigned Patents in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns. 6. This instrument will be interpreted and construed in accordance with the laws of the State of New York, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement. <p>IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.</p> <p>Date: <u>12/20/12</u></p> <p>RECEIVED AND AGREED TO BY ASSIGNEE: Date: <u>12-20-12</u></p> <p>ASSIGNOR By: <u>[Signature]</u> Name: Bryan C. Zielinski Title: Attorney-in-Fact</p> <p>By: <u>[Signature]</u> Name: Steven James Title: Chairman CEO & PRES <u>[Signature]</u></p>	

COUNTRY	APPLICATION NUMBER	APPLICATION DATE	PATENT NUMBER	GRANT DATE
PC19499: ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME				
A.R.I.P.O.	AP/P2008/004467	02-Nov-2006		
Algeria	80301	02-Nov-2006	5865	14-Sep-2010
Australia	2006313434	02-Nov-2006	2006313434	09-Feb-2012
Australia	2011211388	11-Aug-2011		
Barbados	2001/1404	02-Nov-2006		
Brazil	PI0618705-6	02-Nov-2006		
Canada	2626120	02-Nov-2006		
China P.R.	200680042443.0	02-Nov-2006		
China P.R.	201210315699.1	27-Aug-2012		
Colombia	08-048.296	02-Nov-2006		
Costa Rica	9975	02-Nov-2006		
Cuba	2008-0088	02-Nov-2006		
Ecuador	SP-08-8451	02-Nov-2006		
Egypt	PCT712/2008	02-Nov-2006		
El Salvador	2008002905	02-Nov-2006		
Eurasian Patent Convention	200801094	02-Nov-2006	15526	30-Aug-2011
European Patent Convention	6809207.1	02-Nov-2006		
European Patent Convention	11166787.9	19-May-2011		
Georgia	AP2006010693	02-Nov-2006		
Georgia	AP2006012056	12-Jan-2011		
Hong Kong	9104118	05-May-2009		
India	3854/DELNP/2008	02-Nov-2006		
Indonesia	W-00200801490	02-Nov-2006		
Israel	219503	02-Nov-2006		
Israel	190876	02-Nov-2006		
Japan	2008-540715	02-Nov-2006		
Korea South	10-2008-7011418	02-Nov-2006		
Korea South	10-2011-7020735	05-Sep-2011		
Kosovo	031	13-May-2008		
Malaysia	PI20081383	02-Nov-2006		
Mexico	MX/a/2008/006274	02-Nov-2006	296896	08-Mar-2012
Mexico	MX/a/2012/000343	05-Jan-2012		
Mongolia	4138	02-Nov-2006	3176	02-May-2008
Montenegro	P-623/08	10-Nov-2009	419	10-Oct-2011
Morocco	30924	02-Nov-2006	30136	02-Jan-2009

COUNTRY	APPLICATION NUMBER	APPLICATION DATE	PATENT NUMBER	GRANT DATE
New Zealand	593971	02-Nov-2006		
New Zealand	568237	02-Nov-2006	568237	05-Mar-2012
Nicaragua	2008-0141-I	02-Nov-2006		
Norway	20081854	02-Nov-2006		
O.A.P.I.	1200800183	02-Nov-2006		
Patent Cooperation Treaty	PCT/IB2006/003181	02-Nov-2006		
Philippines	1-2008-501056	02-Nov-2006		
Serbia	P-200/2008	02-Nov-2006		
Singapore	200803322-7	02-Nov-2006	142380	31-Mar-2011
Singapore	201008335-0	12-Nov-2010		
South Africa	2008/03484	02-Nov-2006	2008/03484	25-Mar-2009
Sri Lanka	PCT/IB2006/003181	02-Nov-2006		
Trinidad & Tobago	TT/A/2008/00087	02-Nov-2006		
Tunisia	SN08213	02-Nov-2006		
Ukraine	a200806484	02-Nov-2006	94244	26-Apr-2011
United States	60/736623	14-Nov-2005		
United States	12/093638	02-Nov-2006	8007794	30-Aug-2011
United States	13/179846	11-Jul-2011		
Uzbekistan	IAP20080178	02-Nov-2006	IAP04207	29-Jul-2010
Vietnam	1-2008-01461	02-Nov-2006		
PC33920: METHODS FOR TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE				
Australia	2010288194	23-Aug-2010		
Brazil	BR112012004464-8	23-Aug-2010		
Canada	2771186	23-Aug-2010		
China P.R.	201080038586.0	23-Aug-2010		
European Patent Convention	10754584	23-Aug-2010		
India	2521/DELNP/2012	23-Aug-2010		
Israel	218228	23-Aug-2010		
Japan	2010-190737	27-Aug-2010		
Korea South	10-2012-7004982	23-Aug-2010		
Mexico	MX/a/2012/002464	23-Aug-2010		
Patent Cooperation Treaty	PCT/IB2010/053787	23-Aug-2010		
Russian Federation	2012106468	23-Aug-2010		
United States	61/237901	28-Aug-2009		
United States	13/392860	23-Aug-2010		